This presentation focuses on Acute Bacterial Meningitis.
Viral and fungal cause is mentioned but focus is on bacterial meningitis in Pediatrics Patient.
Feel free to correct if there is any error.
Refer to other reference books for clarity.
This presentation focuses on Acute Bacterial Meningitis.
Viral and fungal cause is mentioned but focus is on bacterial meningitis in Pediatrics Patient.
Feel free to correct if there is any error.
Refer to other reference books for clarity.
simlpe approach to anemia in children , how to diagnose anemia in kids ,types of anemias ,causes of anemia , iron deficeincy anemia, hemolytic anemias , laboratory tests in anemia ,
Definition of neonatal sepsis,type of neonatal sepsis ,early onset neonatal sepsis,late onset neonatal sepsis,Pathophysiology of neonatal sepsis,,sign and symptoms of neonatal sepsis, diagnosis of neonatal sepsis,management of neonatal sepsis, antibiotic used for neonatal sepsis,prevention of neonatal sepsis, prognosis of neonatal sepsis ,and A summary
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES - Slideset by professor Susanna Esposito, president WAidid, presented at the 7th International Congress of Laboratory and Clinic, held in Tehran (Iran) from 12 to 14 February 2015
simlpe approach to anemia in children , how to diagnose anemia in kids ,types of anemias ,causes of anemia , iron deficeincy anemia, hemolytic anemias , laboratory tests in anemia ,
Definition of neonatal sepsis,type of neonatal sepsis ,early onset neonatal sepsis,late onset neonatal sepsis,Pathophysiology of neonatal sepsis,,sign and symptoms of neonatal sepsis, diagnosis of neonatal sepsis,management of neonatal sepsis, antibiotic used for neonatal sepsis,prevention of neonatal sepsis, prognosis of neonatal sepsis ,and A summary
DIAGNOSIS OF PEDIATRIC INFECTIOUS DISEASES - Slideset by professor Susanna Esposito, president WAidid, presented at the 7th International Congress of Laboratory and Clinic, held in Tehran (Iran) from 12 to 14 February 2015
Clinical Impact of New Data From AIDS 2018hivlifeinfo
Clinical Impact of New Data From AIDS 2018
July 23-27, 2018; Amsterdam, The Netherlands
Expert faculty members summarize key studies from this important annual conference.
The approach to neonatal bacterial infections - Irja LutsarWAidid
Professor Irja Lutsar (Tartu, Estonia) focuses on bacterial infections in neonates: she shows types and origins of neonatal sepsis and goes through the available treatments.
Fnd out more on www.waidid.org!
Treatment of Multidrug-resistant and Extensively Drug-Resistant Tuberculosis ...WAidid
Slideset by professor G.B. Migliori, Chair of WAidid Working group on Tuberculosis and WHO Collaborating Centre for TB and Lung Disease, Fondazione S. Maugeri, Care and Research Institute Tradate, Italy
Find more on www.waidid.com
Susanna Esposito (president WAidid) - Infections and vaccines in pediatricsWAidid
Slideset presented by professor Susanna Esposito, president WAidid, in occasion of the 25th ECCMID held last April in Copenhagen. The slideset was used to support professor Esposito top paper in paediatric infectious diseases
This presentation focuses on a procedure of enteral nutrition: Percutaneous Endoscopic Gastrostomy procedure, Common complications & Risk factors predicting complications
This presentation focuses on a procedure of enteral nutrition: Percutaneous Endoscopic Gastrostomy procedure, Common complications & Risk factors predicting complications
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Knee anatomy and clinical tests 2024.pdfvimalpl1234
This includes all relevant anatomy and clinical tests compiled from standard textbooks, Campbell,netter etc..It is comprehensive and best suited for orthopaedicians and orthopaedic residents.
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Recomendações da OMS sobre cuidados maternos e neonatais para uma experiência pós-natal positiva.
Em consonância com os ODS – Objetivos do Desenvolvimento Sustentável e a Estratégia Global para a Saúde das Mulheres, Crianças e Adolescentes, e aplicando uma abordagem baseada nos direitos humanos, os esforços de cuidados pós-natais devem expandir-se para além da cobertura e da simples sobrevivência, de modo a incluir cuidados de qualidade.
Estas diretrizes visam melhorar a qualidade dos cuidados pós-natais essenciais e de rotina prestados às mulheres e aos recém-nascidos, com o objetivo final de melhorar a saúde e o bem-estar materno e neonatal.
Uma “experiência pós-natal positiva” é um resultado importante para todas as mulheres que dão à luz e para os seus recém-nascidos, estabelecendo as bases para a melhoria da saúde e do bem-estar a curto e longo prazo. Uma experiência pós-natal positiva é definida como aquela em que as mulheres, pessoas que gestam, os recém-nascidos, os casais, os pais, os cuidadores e as famílias recebem informação consistente, garantia e apoio de profissionais de saúde motivados; e onde um sistema de saúde flexível e com recursos reconheça as necessidades das mulheres e dos bebês e respeite o seu contexto cultural.
Estas diretrizes consolidadas apresentam algumas recomendações novas e já bem fundamentadas sobre cuidados pós-natais de rotina para mulheres e neonatos que recebem cuidados no pós-parto em unidades de saúde ou na comunidade, independentemente dos recursos disponíveis.
É fornecido um conjunto abrangente de recomendações para cuidados durante o período puerperal, com ênfase nos cuidados essenciais que todas as mulheres e recém-nascidos devem receber, e com a devida atenção à qualidade dos cuidados; isto é, a entrega e a experiência do cuidado recebido. Estas diretrizes atualizam e ampliam as recomendações da OMS de 2014 sobre cuidados pós-natais da mãe e do recém-nascido e complementam as atuais diretrizes da OMS sobre a gestão de complicações pós-natais.
O estabelecimento da amamentação e o manejo das principais intercorrências é contemplada.
Recomendamos muito.
Vamos discutir essas recomendações no nosso curso de pós-graduação em Aleitamento no Instituto Ciclos.
Esta publicação só está disponível em inglês até o momento.
Prof. Marcus Renato de Carvalho
www.agostodourado.com
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?
Neonatal Meningitis
1. Bacterial meningitis in
infants <90 days of age:
burden of disease &
assessment of healthcare
deliveryDr Ifeanyichukwu O Okike & Prof Paul T
Heath
St George’s, University of London
MRF Symposium, Bristol
2. “It was a living nightmare watching our baby so ill
and fighting for his life” Parent of a baby with GBS
meningitis
Courtesy of MRF &
3. The rate in <3month-olds is >70 x that of
adults
All p values <0.0001
bacterial meningitis in E+W, 2004-
2011 (PHE, LabBase2)
Age group % of total
population
No of
cases (%)
Incidence (95% CI)
(/ 100,000
population)
Incidence
Rate Ratio
< 3months 0.3 978 (16) 72.19 (67.74-76.86) 136 (118-
155)
3-11
months
0.9 755 (12) 18.58 (17.27-19.95) 35 (30-40)
1-4 years 4.7 522 (8) 2.54 (2.33-2.77) 4.8 (4.1-5.5)
5-14 years 11.6 270 (4) 0.53 (0.47-0.60) Reference
15-44 years 41.0 1538 (25) 0.86 (0.82-0.91) 1.6 (1.4-1.8)
45-64 years 25.3 1331 (22) 1.21 (1.14-1.27) 2.3 (2.0-2.6)
≥65 years 16.2 752 (12) 1.07 (0.99-1.15) 2.0 (1.7-2.3)
Okike et al Lancet Infectious diseases:
2014;14(4): 301 - 307
4. Location Period / 1000 LB Fatality (%) Sequelae
Leeds 1947-1960 0.5
NW Thames 1969-1973 0.26
Nottingham 1980-1989 0.37 25
Oxford region 1984-1991 0.25 26
E+W 1985-1987 0.22 25 50%
E+W 1996-1997 0.21 10 51%
E+W* 2010-2011 0.21 11
Lancet. 1976;1:701 Arch Dis Child 1991;66:603-7 Arch Dis Child Fetal Neonatal Ed 2001;84:F85-9
* Okike et al (accepted CID 2014)
Neonatal meningitis
surveillance studies in E+W
(≤28 days of age)
E+W= England &
Wales
5. Bacteria 1985-87
(0.22/1000)
1996-97
(0.21/1000)
2010-11*
(0.21/1000)
GBS 38% 48% 60%
E. coli 25% 18% 14%
S.
pneumoniae
6% 6% 6%
L.
monocytogen
es
7% 5% 3%
N.
meningitidis
4% 4% 2%
Other Gram
neg
12% 8% 8%
Aetiology of neonatal (0-28 days of
age) current vs historical for England &
Wales
Arch Dis Child 1991;66:603-7 . Arch Dis Child Fetal Neonatal Ed 2001;84:F85-9
* Okike et al (accepted CID 2014)
6. Bacteria All 1st
month
2nd
month
3rd
month
Group B
strep
50 58 47 24
E. coli 13 15 12 11
S.
pneumoniae
9 6 7 29
N.
meningitidis
8 2 15 24
in infants <3 months of life in the
UK
No case of Listeria meningitis after 29
days of ageOkike et al accepted CID 2014
7. Identified bacteria:
by route of admission & gestation at
birth
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
Home (term) Home (preterm) In-patient (term) In-patient (preterm)
Percentageofcases
Route of admission and maturity at birth
N. meningitidis
Other G negative
E. coli
Other G positive
L. monocytogenes
Non pyogenic streptococci
S. pneumoniae
Group B strep
47%
E0 = 5
(29%)
LO= 12
(71%)
8. Comparison of aetiology with other international studie
GBS:
86.1%
0%
10%
20%
30%
40%
50%
60%
70%
80%
90%
100%
<2mo
Percentageoftotalcases
GBS:
78.1%
USA 2003-07 UK & ROI 2010-11Cases < 2 months of age
Thigpen et al. N Engl J Med 2011; 364:2016-2025 Okike et al accepted CID 2014
9. 0%
10%
20%
30%
40%
50%
60%
70%
80%
Percentageofcases
Presenting features
All
0-28 d
>28 d
Non-specific Specific
Presenting features
(n=329)Combination of features Percentage of
cases
Fever and irritability 41%
Fever and lethargy 33%
Fever, lethargy and poor feeding 29%
Fever, irritability and poor
perfusion
19%
Fever and convulsion 11%
Convulsion and bulging
fontanelle
7%
Convulsion, bulging fontanelle
and neck stiffness
1%
10. Presenting features: GBS vs. others
0%
10%
20%
30%
40%
50%
60%
70%
80%
Percentageoftotalcases
Presenting features
GBS
Other bacteria
Non specific Specific
p=0.001
12. Role of LP in making a diagnosis
[X2, p=0.001]
Timing of LP No bacteria in the CSF (%)
Pre antibiotics 27 (21)
Post antibiotics 103 (79)
• LP was done in 315/329 (96%)
• Post antibiotics 197/307 (64%)
- in-patient vs. home admissions: 84% vs.
52%, p<0.0001
Okike et al (accepted CID 2014)
13. Combination All: N
(%)
Home admission: N
(%)
In patient: N
(%)
Amoxicillin/ Ampicillin and Cephalosporin 84 (26) 76 (38) 7 (6)
Cephalosporin only 64 (20) 47 (24) 17 (14)
Benzyl penicillin and Gentamicin/ Amikacin 64 (20) 20 (10) 44 (37)
Benzyl penicillin and Cephalosporin and
Gentamicin
19 (6) 12 (6) 7 (6)
Cephalosporin and Gentamicin 15 (5) 11 (6) 4 (3)
Amoxicillin/ Ampicillin and Cephalosporin and
Gentamicin
13 (4) 11 (6) 2 (2)
Benzyl penicillin and Cephalosporin 11 (3) 7 (4) 4 (3)
Amoxicillin and Gentamicin 11 (3) 6 (3) 5 (4)
Flucloxacillin and Gentamicin 8 (2) 0 (0) 7 (6)
Cefotaxime and Flucloxacillin 6 (2) 3 (2) 3 (3)
Benzyl penicillin only 3 (1) 3 (2) 0 (0)
Tazocin and Vancomycin 3 (1) 0 (0) 3 (3)
Other* 21 (7) 3 (2) 16 (13)
TOTAL 322
(100)
199 (100) 119 (100)
Empiric Antibiotics used
70% of ≤ 28day-olds received a Penicillin
50% of >1month-olds received a Penicillin
Only 38% of home admissions used empiric
antibiotics as per NICE: Amoxicillin &
Cefotaxime.
14. Our study Vs. Empiric antibiotic
therapy:
Audit of UK & Ireland Unit policies
*Journal of Antimicrobial Chemotherapy (2008) 61, 743–745. ** BPSU study 2010-2011
Antibiotic Audit 2006*,
n(%): 202
units
Okike et al**
in-patient, n(%): 119
cases
Include
a cephalosporin
96 (45) 48 (40)
Cephalosporin
monotherapy
25 (12) 17 (14)
Does not include
a Penicillin
39 (19) 49 (41)
Cephalosporin +
a penicillin +
+
Aminoglycosides
11 (5) 9 (8)
If we assume current- inpatient represent NNUs
16. Organism Total Died (%) *Complication in survivors (%)
None detected 65 2 (3) 5 (8)
Group B strep 135 7 (5) 28 (22)
E. coli 35 3 (9) 7 (22)
S. pneumoniae 26 5 (19) 11 (52)
N. meningitidis 20 0 (0) 5 (25)
L. monocytogenes 9 0 (0) 2 (22)
Non-pyogenic
streptococci 7 1 (14) 2 (33)
Other Gram positive 11 2 (18) 1 (11)
Other Gram negative 19 5 (26) 4 (29)
Overall Outcome
Overall CFR 25/329 = 7.6% [95% CI: 5.2-11.0], 7-day: 5.8% & 28-
day: 7.3%
Death or any serious complication 90/329 = 27% [95% CI: 23-33]
*seizures 26 (9%), motor disorder/abnormal neurology 24 (8%), hydrocephalus 15 (5%),
abnormal hearing 8 (3%), severe skin/musculoskeletal defect 5 (2%), other 2 (1%) [drainage
17. Variable OR (95% CI) p value
Prematurity (<28 weeks) 4.8 (1.7- 13.1) 0.003
Temperature instability on
admission
2.1 (1.1- 4.2) 0.03
Convulsions on admission 4.5 (2.3 - 8.8) <0.000
1
Coma on admission 10.4 (2.1- 0.004
Independent risk factors for
death / any serious
complication
Features present at the time of admission
Multivariate logistic regression analysis of risk of death or developing a serious
complication.
18. Variable OR (95% CI) p value
Prematurity (<28 weeks) 4.6 (1.8- 11.6) 0.001
Temperature instability on
admission
3.0 (1.5- 5.8) 0.001
Convulsions on admission 4.8 (2.4 - 9.4) <0.000
1
Coma on admission 19.7 (3.9- <0.001
Independent risk factors for
death / any serious
complication
Multivariate logistic regression analysis of risk of death or developing a serious
19. Summary: Burden of disease
Incidence: BM in E+W unchanged in 3
decades (≤28d)
Clinical: Mainly non-specific, ~1 in 2 did not
have fever
Causal bacteria: GBS & E. coli leading causes
Empiric antibiotics: wide variation used,
consensus?
Neonates from home & term IP: Amox + CTX,
Home & term IP >1 mo: CTX
IP & preterm: consider meropenem
Outcome: Death/ acute complication : 27% of
cases
21. Bacterial meningitis in infants <90
days: assessment of healthcare
delivery
Objectives
• To describe the early presenting features
• To review pre hospital management
• To review in-hospital & discharge
management
• To determine the long-term
neurodevelopmental outcome of infants <90
Preliminary data
22. Methodology (between Sept 2010- July
2013)
Participant Identification centres (PICS)
95 NHS Trusts in England, 7 health boards
in Wales
Parental Pack (Study information, Consent form,
parental questionnaire for onset to progression)
Hospital review of case management
(Research Fellow visits hospital to review case
management)
Expert panel review of case management
(PID, Neonatologist, General Paediatrician,
trainee)
Inclusion: Significant bacterial pathogen from CSF or from blood culture &
csf pleocytosis
(≥20 cells : m3 for babies 0-28d old & ≥10cells/ mm3 for babies 29-89d)
Exclusion criteria: Intraventricular shunt device, spina bifida
Ethics Cambs 2
REC: Ref:
10/H0308/64
Public Health England
Support charities (parents)
Paediatricians (PICs)
23. Recruitment
322 packs sent to
Paediatricians
271 packs eligible to be sent to parents
227 packs confirmed to have been sent to
parents
103 Consented to take part
97 Eligible for analysis
51 packs not sent to parents
(not cases or not appropriate to
send)
44 packs were not confirmed as sent
124 did not return consent form
45% recruitment rate
94% eligible for analysis
Viral: 4
No organism: 2
24. 13 (13%)
Median age: 14 days (IQR: 3-25)
Admitted from home: 66 (68%)
Recruited =103, included
cases=97*
*1 case from
Wales
26 (27%)
18 (19%)
39 (41%)
26. Cases already on NNU at
diagnosis
Category Value
Male 18 (58%)
Age in days: median (IQR) 1 (0-7)
Prematurity (<37 weeks) 15 (48%)
Risk factors for EO neonatal infection
including red flags
9 (29%)
27. Summary
THERE APPEAR TO BE SIGNIFICANT OPPORTUNITIES
TO IMPROVE EARLY HEALTHCARE DELIVERY!
- Pre hospital management inappropriate in 41% of cases
- Delay in antibiotics >1 hour in 73% (home) & 82% (IP)
- Inappropriate empiric antibiotics: 52% (home) & 61% (IP)
- 38% of home admissions discharged at age < 2years
- 16% of IP cases discharged at age < 2 years
(NB. follow up of 1980s & 90s survivors showed sequelae in
50%)
- Quality of clinical practice needs improvement
BMJ 2001;323:1-5; Eur J Pediatr 2005;164:730–4
28. Next steps…
Towards better outcomes for bacterial
meningitis
Prevention
- GBS vaccines (ClinicalTrials.gov, number
NCT01193920)
- Pneumococcal conjugate vaccines (herd immunity: PCV
13)
- Hygiene strategies during pregnancy (listeria)
- Improving infection prevention & control practices in
NNUs
Improve early management
- Education of parents (Orange book ,Your Guide, update
Baby watch)
31. AMR & HCAI
Prof. Alan Johnson
Katherine Henderson
Ruth Blackburn
Dr. Berit Muller-Pebody
MRL Manchester
Prof. Ray Borrow
Dr. Claire Cameron
Dr. Alison Smith-Palmer
Dr. Eisin McDonald
Chief Investigator
Prof Paul T Heath
Dr Nelly Ninis (London)
Dr. Mark Anthony (Oxford)
Dr. Laura Jones (Edinburgh)
Prof Mary Cafferkey
(Ireland)
Dr. Katy Sinka (Scotland)
Dr. Robert Cunney
(HSE Ireland)
Helen Friend
Richard Lynn
All Paediatricians
in the UK & the RoI
Support Charities:
Meningitis UK/ Meningitis
Trust
and Group B Strep Support
St George’s Vaccine Institute
staff
Others
Dr Eva Galiza
Dr. S Ladhani
UK & ROI Paediatricians and PIC
contacts (HCD)
Acknowledgements
Funding
meningitis@sgul.ac.
uk
Families &
infants
affected